DCAL Share Price Performance
₹284.05
109.44 (62.68%)
Price ₹284.05
Share Price₹284.05
Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?
Jun 23
Dishman Carbogen Amcis Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
DCAL Community Narratives
There are no narratives available yet.
Dishman Carbogen Amcis Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 6.65
- Gross Margin
- 81.48%
- Net Profit Margin
- 3.60%
- Debt/Equity Ratio
- 41.0%
Dishman Carbogen Amcis Limited Competitors
Snowflake Analysis
About DCAL
- Founded
- 1983
- Employees
- 1106
- CEO
- WebsiteView website
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Indian Market Performance
- 7 Days: 1.5%
- 3 Months: -1.7%
- 1 Year: -4.7%
- Year to Date: 0.7%
The market is up 1.5% over the last week, with the Financials sector leading the way, up 2.3%. Longer term the market is actually down 4.7% over the past year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›